NASDAQ:SVA - Sinovac Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.43 -0.22 (-3.31 %)
(As of 02/17/2019 09:35 AM ET)
Previous Close$6.43
Today's Range$6.31 - $6.65
52-Week Range$5.73 - $8.75
Volume48,812 shs
Average Volume7,431 shs
Market Capitalization$366.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines. In addition, it has completed Phase I/II clinical trials for Sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate vaccine, rubella vaccine, and quadrivalent influenza vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; and Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVA
CUSIPN/A
Phone86-10-5693-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$174.35 million
Cash Flow$0.5067 per share
Book Value$3.11 per share

Profitability

Miscellaneous

Employees644
Market Cap$366.63 million
OptionableOptionable

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

When is Sinovac Biotech's next earnings date?

Sinovac Biotech is scheduled to release their next quarterly earnings announcement on Friday, May 10th 2019. View Earnings Estimates for Sinovac Biotech.

Has Sinovac Biotech been receiving favorable news coverage?

News coverage about SVA stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sinovac Biotech earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Sinovac Biotech's key competitors?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:
  • Dr. Weidong Yin, Pres, CEO, Sec. & Vice-Chairman (Age 54)
  • Ms. Nan Wang, CFO & VP of Bus. Devel. (Age 53)
  • Mr. Ming Xia, VP of Sales & Marketing (Age 45)

Who are Sinovac Biotech's major shareholders?

Sinovac Biotech's stock is owned by many different of retail and institutional investors. Top institutional investors include Neumann Advisory Hong Kong Ltd (0.55%), Sapphire Star Partners LP (0.18%), Eqis Capital Management Inc. (0.07%), Navellier & Associates Inc (0.05%) and Ramsey Quantitative Systems (0.02%). Company insiders that own Sinovac Biotech stock include James Todd Parsons and Scott Langille. View Institutional Ownership Trends for Sinovac Biotech.

Which institutional investors are selling Sinovac Biotech stock?

SVA stock was sold by a variety of institutional investors in the last quarter, including Neumann Advisory Hong Kong Ltd, Eqis Capital Management Inc. and Navellier & Associates Inc. View Insider Buying and Selling for Sinovac Biotech.

Which institutional investors are buying Sinovac Biotech stock?

SVA stock was acquired by a variety of institutional investors in the last quarter, including Ramsey Quantitative Systems and Sapphire Star Partners LP. View Insider Buying and Selling for Sinovac Biotech.

How do I buy shares of Sinovac Biotech?

Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $6.43.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $366.63 million and generates $174.35 million in revenue each year. Sinovac Biotech employs 644 workers across the globe.

What is Sinovac Biotech's official website?

The official website for Sinovac Biotech is http://www.sinovac.com.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 102200. The biopharmaceutical company can be reached via phone at 86-10-5693-1800 or via email at [email protected]


MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel